Clinical trial NCT03541525: Pathophysiological Explorations of Red Blood Cells
Official title: Pathophysiological Explorations of Red Blood Cells
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Red Blood Cell Disorder
Lead sponsor: Imagine Institute
Sponsor class: OTHER
First posted: 2018-05-30
Enrollment: 3750
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Inclusion of patients affected by red blood cell disorder and their non affected relatives

Brief summary: GR-Ex is a program labelled by Labex (Laboratory of Excellence) by the French Ministry of Higher Education and Research. This program aims to develop the means to improve knowledge in the physiology and pathologies of erythropoiesis, red blood cells and iron metabolism, and to develop new therapeutic protocols capable of providing added value in terms of innovation.


Eligibility criteria: Inclusion Criteria:

* To be affected or have a family history of disease bound to the red blood cell,
* For adult subjects, have signed an informed consent form,
* For minor or major under legal safeguard subjects, the form must be signed by both parents (for minors) or by the legal representative,
* Be affiliated to health insurance.

Exclusion Criteria:

* Being deprived of freedom

Primary outcomes:
measure: Innovative markers of spleen fonctionality
timeFrame: 20 years
measure: Quantification of inflammation in sickle cell disease
timeFrame: 20 years
measure: Markers of post-artesunate hemolysis
timeFrame: 20 years
measure: Correlation between transfusion yield and the storage of red blood cell bags
timeFrame: 20 years
measure: Efficiency of Phosphodiesterase inhibitor on neutrophil adhesion in Sickle cell disease
timeFrame: 20 years
measure: Quantification of mitochondria removal during erythropoiesis in SDC patients, consequences on the mature RBC
timeFrame: 20 years
measure: Study of iron metabolism in Diamond-Blackfan Anemia patients
timeFrame: 20 years
Secondary outcomes:
Other outcomes:
Locations:
city: Cotonou
country: Benin
facility: CHU Hôpital de la Mère et de l'enfant Lagune
city: Amiens
country: France
facility: CHU Amiens-Picardie
city: Antony
country: France
facility: Hôpital Privé d'Antony
city: Bobigny
country: France
facility: Hôpital Avicenne
city: Bordeaux
country: France
facility: Hôpital Pellegrin
city: Clichy
country: France
facility: Hôpital Beaujon
city: Colombes
country: France
facility: Hôpital Louis Mourier
city: Créteil
country: France
facility: Hopital Henri Mondor
city: Le Kremlin-Bicêtre
country: France
facility: CHU Kremlin Bicetre
city: Marseille
country: France
facility: Hopital de la conception
city: Marseille
country: France
facility: Hôpital d'Enfants de la TIMONE
city: Montpellier
country: France
facility: Hôpital Saint Eloi
city: Niort
country: France
facility: CHU de Niort
city: Paris
country: France
facility: Groupe Hospitalier Diaconesses Croix Saint Simon
city: Paris
country: France
facility: Hopital Necker - Enfants malades
city: Paris
country: France
facility: Hôpital Armand Trousseau
city: Paris
country: France
facility: Hôpital Cochin
city: Paris
country: France
facility: Hôpital Européen Georges-Pompidou
city: Paris
country: France
facility: Hôpital Robert Debré
city: Paris
country: France
facility: Hôpital Saint Louis
city: Paris
country: France
facility: Hôpital Saint-Antoine
city: Paris
country: France
facility: Institut Pasteur
city: Rouen
country: France
facility: CHU de Rouen
city: Saint-Mandé
country: France
facility: Hôpital national d'instruction des armées Bégin
city: Pointe-à-Pitre
country: Guadeloupe
facility: CHU de la Guadeloupe
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Olivier Hermine, MD, PhD
role: STUDY_DIRECTOR
References: